Online inquiry

IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8627MR)

This product GTTS-WQ8627MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8627MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2033MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ9219MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ4916MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ15945MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ10624MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ7598MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ2610MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ8536MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5A8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW